🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. dexlansoprazole injection

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 1 small molecule completed

    1 trial

  2. domestic polysaccharide superparamagnetic iron oxide nanoparticle

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  3. fRPE cells

    The First People's Hospital of Lianyungang

    Age Related Macular Degeneration

    phase 1 small molecule active

    1 trial

  4. hCD19.IL15.CAR-iNKT

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  5. human HER2-targeted CAR-M cells

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 1 mab active

    1 trial

  6. narfurine hydrochloride orally disintegrating tablets

    The First People's Hospital of Lianyungang

    Improvement of Pruritus in Hemodialysis Patients

    phase 1 small molecule active

    1 trial

  7. pd-1 and DC-NK cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  8. pd-1 and dc-cik cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  9. prophylactic 4SCAR19 cells

    The First People's Hospital of Lianyungang

    B Acute Lymphoblastic Leukemia

    phase 1 gene therapy active

    1 trial

  10. salvianolic acid A

    The First People's Hospital of Lianyungang

    Diabetes

    phase 1 small molecule active

    1 trial

  11. salvianolic acid A

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule active

    1 trial

  12. standard chemotherapy medicine combined with Chinese herbs

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  13. stem cells

    The First People's Hospital of Lianyungang

    Diminished Ovarian Response

    phase 1 other active

    1 trial

  14. suramin sodium

    The First People's Hospital of Lianyungang

    Hand, Foot and Mouth Disease

    phase 1 small molecule active

    1 trial

  15. triple-branched stent graft

    The First People's Hospital of Lianyungang

    Acute Aortic Dissection

    phase 1 other active

    1 trial

  16. universal CLL1 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  17. γδT Cell infusion agent

    The First People's Hospital of Lianyungang

    Leukemia, B-cell

    phase 1 small molecule active

    1 trial

  18. "Nefecon®","Ambrisentan"

    The First People's Hospital of Lianyungang

    IgA Nephropathy

    approved small molecule active

    1 trial

  19. 20mg Febuxostat

    The First People's Hospital of Lianyungang

    Hyperuricemia

    approved small molecule active

    1 trial

  20. 37.5mg Pregabalin + 75mg Pregabalin

    The First People's Hospital of Lianyungang

    Pain, Postoperative

    approved small molecule completed

    1 trial

  21. ALA

    The First People's Hospital of Lianyungang

    Actinic Keratoses

    approved small molecule active

    1 trial

  22. AN69ST hemofilter

    The First People's Hospital of Lianyungang

    Critical Ill Patients

    approved other completed

    1 trial

  23. Aerosolized 13 cis retinoic acid plus Vitamin D

    The First People's Hospital of Lianyungang

    Post COVID-19 Anosmia (Loss of Smell)

    approved small molecule active

    1 trial

  24. Alprostadil

    The First People's Hospital of Lianyungang

    Stroke

    approved small molecule active

    1 trial

  25. Amlodipine besylate

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  26. Anti-peristaltic ileosigmoid anastomosis

    The First People's Hospital of Lianyungang

    Constipation

    approved other completed

    1 trial

  27. Aspirin

    The First People's Hospital of Lianyungang

    G6PD Deficiency

    approved small molecule active

    1 trial

  28. Aspirin

    The First People's Hospital of Lianyungang

    Recurrent Pregnancy Loss

    approved small molecule active

    1 trial

  29. Azvudine

    The First People's Hospital of Lianyungang

    COVID-19

    approved small molecule active

    1 trial

  30. Babaodan oral capsule

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  31. Basiliximab

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    1 trial

  32. Basiliximab,

    The First People's Hospital of Lianyungang

    Beta-Thalassemia Major

    approved small molecule completed

    1 trial

  33. Berberine

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  34. Blinatumomab

    The First People's Hospital of Lianyungang

    Acute B-cell Lymphoblastic Leukemia

    approved small molecule active

    1 trial

  35. Budesonide 200 microgram/Puff, HFA MDI

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule completed

    1 trial

  36. Bupivacaine Hydrochloride

    The First People's Hospital of Lianyungang

    Pulmonary Nodule

    approved small molecule active

    1 trial

  37. Busulfan

    The First People's Hospital of Lianyungang

    Thalassemia Major

    approved small molecule completed

    1 trial

  38. Butylphthalide

    The First People's Hospital of Lianyungang

    Focal Epilepsy

    approved small molecule active

    1 trial

  39. CFNB group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial

  40. CSII

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  41. CTB group

    The First People's Hospital of Lianyungang

    Post-operative Pain

    approved other active

    1 trial

  42. Calcitriol

    The First People's Hospital of Lianyungang

    Glomerulonephritis

    approved small molecule active

    1 trial

  43. Chemoembolization and Response-Dependent Resection

    The First People's Hospital of Lianyungang

    Resectable Hepatocellular Carcinoma Beyond Milan Criteria

    approved other active

    1 trial

  44. Cholecalciferol

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis-associated Peritonitis

    approved small molecule active

    1 trial

  45. Cilostazol

    The First People's Hospital of Lianyungang

    Cerebral Small Vessel Disease

    approved small molecule active

    1 trial

  46. Cinobufacini injection

    The First People's Hospital of Lianyungang

    Liver Cancer

    approved small molecule active

    1 trial

  47. Ciprofol

    The First People's Hospital of Lianyungang

    Postoperative Delirium (POD)

    approved small molecule active

    1 trial

  48. Ciprofol

    The First People's Hospital of Lianyungang

    ECMO Treatment

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.